Profile data is unavailable for this security.
About the company
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
- Revenue in HKD (TTM)441.75m
- Net income in HKD-1.31bn
- Incorporated2017
- Employees605.00
- LocationAscentage Pharma Group International68 Xinqing Road, Suzhou Industrial ParkSuzhou ChinaCHN
- Websitehttps://www.ascentage.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GenFleet Therapeutics (Shanghai) Inc | 219.10m | -1.05bn | 11.19bn | 94.00 | -- | -- | -- | 51.08 | -3.04 | -3.04 | 0.6344 | -8.66 | -- | -- | -- | -- | -- | -- | -- | -- | 80.86 | -- | -479.17 | -- | 0.1655 | -23.43 | -- | -- | 42.00 | -- | -33.31 | -- | -- | -- |
| Suzhou Ribo Life Science Co Ltd | 204.02m | -250.00m | 11.95bn | 404.00 | -- | -- | -- | 58.56 | -1.55 | -1.55 | 1.26 | -0.4093 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
| Nanjing Leads Biolabs Co Ltd | 0.00 | -325.29m | 12.20bn | 192.00 | -- | 97.39 | -- | -- | -2.01 | -2.01 | 0.00 | 0.6299 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
| Keymed Biosciences Inc | 987.84m | -291.46m | 16.30bn | 1.47k | -- | 4.50 | -- | 16.50 | -1.11 | -1.11 | 3.75 | 12.11 | 0.2068 | 0.3382 | 15.10 | 785,244.60 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Ascentage Pharma Group International | 442.39m | -1.31bn | 17.73bn | 605.00 | -- | 21.98 | -- | 40.08 | -4.02 | -4.02 | 1.35 | 2.16 | 0.1270 | 3.70 | 0.9505 | 780,234.30 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
| Genscript Biotech Corp | 4.31bn | 644.58m | 26.33bn | 5.77k | 39.55 | 0.7597 | 44.96 | 6.10 | 0.3044 | 11.44 | 2.02 | 15.85 | 0.1259 | 5.94 | 4.39 | 774,704.90 | 0.3949 | -9.75 | 0.4933 | -13.19 | 51.78 | 52.05 | 3.14 | -46.54 | 1.90 | 1.18 | 0.0471 | -- | 6.07 | 16.81 | -115.90 | -- | 5.78 | -- |
Data as of Feb 13 2026. Currency figures normalised to Ascentage Pharma Group International's reporting currency: Hong Kong Dollar HKD
9.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 10.63m | 2.85% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 4.22m | 1.13% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 3.90m | 1.05% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 3.88m | 1.04% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 2.97m | 0.80% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 1.91m | 0.51% |
| Yongying Asset Management Co., Ltd.as of 30 Jun 2025 | 1.88m | 0.50% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 1.88m | 0.50% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 1.73m | 0.46% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.15m | 0.31% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
